Encontrados 240 documentos, a visualizar página 1 de 24

Implementação de um questionário epidemiológico a detentores de explorações cas...

A detenção e a criação de animais em explorações caseiras podem representar um risco para a transmissão de agentes patogénicos zoonóticos e de genes de resistência a antibióticos, com impacto na saúde pública. Em Portugal, a ausência de registo de sistemas de produção caseira (SPC) dificulta a caracterização das práticas de gestão e criação de animais, assim como o perfil dos seus proprietários. Este estudo pil...

Testes rápidos de antigénio e efetividade da vacina contra a COVID-19 nos cuida...

A disponibilização dos testes rápidos de antigénio (TRAg) permitiu que o diagnóstico de infeção por SARS-CoV-2 possa ser feito antes ou durante uma consulta médica. Este conhecimento pode condicionar a procura de cuidados e por outro lado, o Médico de Família (MF) pode ter informação sobre o estado de infeção antes do recrutamento do doente para os estudos de efetividade vacinal. Estudos com desenho de caso-con...

COVID-19 vaccine effectiveness in the paediatric population aged 5-17 years: a ...

Background: During the first year of the COVID-19 pandemic, vaccination programmes targeted children and adolescents to prevent severe outcomes of SARS-CoV-2 infection. Aim: To estimate COVID-19 vaccine effectiveness (VE) against hospitalisation due to COVID-19 in the paediatric population, among those with and without previously documented SARS-CoV-2 infection. Methods: We established a fixed cohort followed f...

Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisati...

We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days ...

Registo Nacional de Anomalias Congénitas: Regiões 2011-2019

Relatório do Registo Nacional de Anomalias Congénitas – Relatório Regiões, referente aos anos de 2011 e 2019, que apresenta os resultados a nível nacional e desagregados a nível das regiões, utilizando-se a Nomenclatura das Unidades Territoriais para Fins Estatísticos, NUTS II. No Relatório RENAC−Regiões apresentado, sobre prevalência de anomalias congénitas e fatores associados, destacam-se os seguintes result...

Mapping susceptibility to air pollution and its association with birth defects:...

Epidemiological studies evaluating the relation of environmental air pollution (AP) and birth defect (BD) are relevant to public health. Some limitations on these studies may derive from multiple factors contributing to the spatial variation of AP. This study aimed to integrate multifactorial AP indicators into an index and explore its application in a case-control study conducted in Portugal between 2016 and 2...

O Impacto do diagnóstico pré-natal e da ecografia obstétrica na deteção de anom...

COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA...

Background: Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. Aim: We aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases. Methods: This European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SAR...

Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adul...

We conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between ...

Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1....

Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hos...